Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Doesn't Bolduc have 4 million plus options and execution on a cashless basis. Oh my. Dilution coming soon from him? At least he will have cash to see the Knicks and a nice NYC apartment?
All stock option agreements applicable to Employee shall be amended to extend the exercise period, solely with respect to options which are vested thereunder as of the Termination Date, from the ninetieth day following such Termination Date to the dates of the original expiration of such options, respectively, so as to permit Employee to exercise solely those options which are vested as of the Termination Date through the expiration dates of said options. Further, such stock option agreements shall be amended to provide for the ability to exercise the vested options on a cashless basis. All other terms of such stock option agreements remain unchanged. See attached schedule of vested shares per agreement.
No more basketball stories? What in blimey does Bolduc have a company apartment in NY for? This thing smells.
GILD does it again: Winner:
Healthcare Picks Sides in Hepatitis C Drug Battle
January 19, 2015, 04:30:35 PM
Laura Joszt
Just days after regulators had approved AbbVie’s Viekira Pak and provided real competition for Gilead Science’s expensive hepatitis C treatments, Express Scripts announced an exclusivity agreement with AbbVie in exchange for a lower price.
Others followed suit. CVS Health backed Gilead almost immediately, with Anthem right behind. Humana also opted to exclusively offer Gilead’s hepatitis C drugs, Sovaldi and Harvoni. Now, Aetna has weighed in on the debate, too. On Friday, the third-largest health insurer in the US announced it had negotiated a discount with Gilead after a clinical review of approved hepatitis C therapies, including Viekira Pak.
Gilead’s Harvoni costs $94,500 for a 12-week course of treatment; however, most patients will be able to take the 8-week course for $63,600. Viekira Pak’s 12-week course costs $83,319. While the presence of a competitor can benefit patients as insurers negotiate lower prices, some are concerned that these exclusivity deals can be harmful because: 1) treatment decisions are being taken out of clinicians’ hands, and 2) they set the precedent of prescribing based solely on cost and not overall outcome considerations.
AdverseEvents, a California-based healthcare informatics company that analyzes drug side effect data, recently released a safety analysis comparing Viekira Pak with Harvoni and Solvadi. According to the results, AbbVie’s drug may have a poorer safety profile, which raises the question of whether Express Scripts’ exclusivity deal was based more on clinical data or the opportunity to lower costs.
While both Viekira Pak and Harvoni list fatigue, headache, nausea, diarrhea, insomnia, and bilirubin elevations as adverse events, Viekira Pak has a long list of adverse events that are absent from Harvoni’s label, including anemia, jaundice, liver inflammation, loss of therapeutic effect, and ulcer. The only additional adverse event listed on Harvoni’s label that is not on Viekira Pak’s is lipase elevations.
So far Express Scripts is the only company to make an exclusivity agreement with AbbVie’s drug. Meanwhile, Prime Therapeutics LLC chose not to pick a side. Instead the pharmacy benefits manager made agreements with both Gilead and AbbVie and will place both Harvoni and Viekira Pak on the preferred drug list, reported Specialty Pharmacy Times.
“There has been a substantial reduction in the net price of both of these drugs just in the past few weeks, so sometimes it pays not to go first,” Peter Wickersham, senior vice president of Integrated Care and Specialty at Prime said in a statement. “It was clear that neither Gilead nor AbbVie wanted to be left off our formulary and the result proved to be significantly better than taking an exclusive position.”
- See more at: http://www.ajmc.com/newsroom/Healthcare-Picks-Sides-in-Hepatitis-C-Drug-Battle#sthash.x5r64C6h.dpuf
Healthcare Picks Sides in Hepatitis C Drug Battle
January 19, 2015, 04:30:35 PM
Laura Joszt
Just days after regulators had approved AbbVie’s Viekira Pak and provided real competition for Gilead Science’s expensive hepatitis C treatments, Express Scripts announced an exclusivity agreement with AbbVie in exchange for a lower price.
Others followed suit. CVS Health backed Gilead almost immediately, with Anthem right behind. Humana also opted to exclusively offer Gilead’s hepatitis C drugs, Sovaldi and Harvoni. Now, Aetna has weighed in on the debate, too. On Friday, the third-largest health insurer in the US announced it had negotiated a discount with Gilead after a clinical review of approved hepatitis C therapies, including Viekira Pak.
Gilead’s Harvoni costs $94,500 for a 12-week course of treatment; however, most patients will be able to take the 8-week course for $63,600. Viekira Pak’s 12-week course costs $83,319. While the presence of a competitor can benefit patients as insurers negotiate lower prices, some are concerned that these exclusivity deals can be harmful because: 1) treatment decisions are being taken out of clinicians’ hands, and 2) they set the precedent of prescribing based solely on cost and not overall outcome considerations.
AdverseEvents, a California-based healthcare informatics company that analyzes drug side effect data, recently released a safety analysis comparing Viekira Pak with Harvoni and Solvadi. According to the results, AbbVie’s drug may have a poorer safety profile, which raises the question of whether Express Scripts’ exclusivity deal was based more on clinical data or the opportunity to lower costs.
While both Viekira Pak and Harvoni list fatigue, headache, nausea, diarrhea, insomnia, and bilirubin elevations as adverse events, Viekira Pak has a long list of adverse events that are absent from Harvoni’s label, including anemia, jaundice, liver inflammation, loss of therapeutic effect, and ulcer. The only additional adverse event listed on Harvoni’s label that is not on Viekira Pak’s is lipase elevations.
So far Express Scripts is the only company to make an exclusivity agreement with AbbVie’s drug. Meanwhile, Prime Therapeutics LLC chose not to pick a side. Instead the pharmacy benefits manager made agreements with both Gilead and AbbVie and will place both Harvoni and Viekira Pak on the preferred drug list, reported Specialty Pharmacy Times.
“There has been a substantial reduction in the net price of both of these drugs just in the past few weeks, so sometimes it pays not to go first,” Peter Wickersham, senior vice president of Integrated Care and Specialty at Prime said in a statement. “It was clear that neither Gilead nor AbbVie wanted to be left off our formulary and the result proved to be significantly better than taking an exclusive position.”
- See more at: http://www.ajmc.com/newsroom/Healthcare-Picks-Sides-in-Hepatitis-C-Drug-Battle#sthash.x5r64C6h.dpuf
Karin, thanks for your response.
That's a plus for Harvoni. A provider, assuming they haven't been bought off by the ABBV rep, would always choose Harvoni. The patient would choose Harvoni too. ENTA collected their cash, for now it's a value trap...imo.
It doesn't make sense to me that they haven't gotten financing, partners, etc to up list. That is a big red flag imo.
The fact that they are staying on the pink sheets is enough of a deterrent, for now, to suggest that this isn't the real deal. The huge drop in stock price means that most aren't secure in their holding. Hopefully you are trading accordingly. All imo.
What is it going to take for this dog to eclipse 2 bucks?
The Prime formulary kills V-Pak since it shares preferred formulary status with Harvoni. Dr to patient: take bid dosing with V-pak and maybe take generic ribvarin, or go on one pill a day with Harvoni. Huge Harvoni win.
Nice call on EDAP! Gotta listen to ya!
It's a dilution machine. I was trading it back then but won't touch it now.
50 RX's for V-Pak. Not bad!
$ABBV predicts sharp increase in earnings the only problem is the $1.5 billion break up fee.
If the RX's for V-Pak are sluggish, timber time. You do trade and don't hold ABBV?
GILD..dominating so far. Duopoly yeah but 80% Harvoni looks like. Poor V-Pack, maybe VPACK will have 28 nrx's this week?
Holding a starter and hoping for $2 if the stock gods allow it?
ABBV didn't have a choice, since price is all they could bargain with. A shame that a cure for Hep C has successfully been commodotized. The next entrant into the Hep C market better offer a lower price than ABBV's if they want to play in the game.
So you don't want to answer the PBM questions? Barry appreciates your support.
ABBV has opened Pandora's box by starting a price war. Essentially, the days of a HUMIRA and a Sovaldi may never happen again. What rate of profitability does the PBM determine is fair? How will a profit ceiling determined by the PBM spur innovation? Very scary and we are just at the beginning of this. Thank you Obama!
The anti-HIV drug zidovudine (see fact sheet 411) can cause anemia and should not be combined with RBV.
and ALL THESE TOO:
abacavir
aldesleukin
aminophylline
antacids containing aluminum or magnesium
azathioprine
Chinese herbal medicine (sho-saiko-to or Xiao Chai Hu )
clozapine
didanosine
emtricitabine
(Big problem) VIEKIRA PAK and RBV drug interactions
MUST NOT TAKE VIEKIRA PAK IF YOU
take any of the following medicines:
alfuzosin hydrochloride (Uroxatral®) -
carbamazepine (Carbatrol®,
Epitol®,
Equetro®,
Tegretol®) - efavirenz
Sustiva®,
Atripla®) - ergot containing medicines including ergotamine tartrate
Cafergot®,
Migergot®,
Ergomar®,
Ergostat®,
Medihaler®,
Wigraine®,
Wigrettes®), dihydroergotamine mesylate
D.H.E. 45®,
Migranal®), methylergonovine
(Ergotrate®,
Methergine®) - ethinyl estradiol-containing medicines - gemfibrozil
(Lopid®) - lovastatin
Advicor®,
Altoprev®,
Mevacor®) - midazolam (when taken by mouth) - phenytoin
Dilantin®,
Phenytek®) - phenobarbital
Luminal®) - pimozide
Orap®) - rifampin
Rifadin®,
Rifamate®,
Rifater®,
Rimactane®) - sildenafil citrate
Revatio®) when taken for pulmonary artery hypertension (PAH) - simvastatin
Zocor®,
Vytorin®,
Simcor®) -
St. John's wort (Hypericum perforatum) or a product that contains St. John's wort - triazolam
Halcion®).
IF WITH RBV, THEN DONT TAKE VIEKIRA IF
YOU TAKE
The anti-HIV drug zidovudine (see fact sheet 411) can cause anemia and should not be combined with RBV.
and ALL THESE TOO:
The real question is if your mother had Hep C, would you prefer her to go on V-pak instead of Harvoni? I didn't think so. Abbv will get some market share but it will be at great rebates as the true demand is for Harvoni.
I think a better comparison is a brand new Honda Accord (Harvoni) vs a Yugo (V-pak). Both will get you to the same place but the Accord will provide a much higher quality ride with less AE's.
All of the ribvarin that has to be taken with VPAK is hardly optional as the comparison chart shows:
https://twitter.com/search?q=%24gild&src=typd&mode=photos
7 pills or 1 pill??? Patients want simple, safets, easiest, most efficacious. The v-pak will be grudgingly used by patients. Seriously, who wants second best? Harvoni is the best choice for patients. Providers are processing prior authorizations because patients know they want one pill a day and don't want second best. Oh, and GILD operates from a position of strength since they don't have a product called Humira going generic in 2016 lol. ABBV can't afford to rebate too much, they don't have a replacement 8 billion plus in sales. Game, set, match Harvoni.
Ribvarin is mandatory. Hardly optional as incorrectly stated. Wait until that news sinks in. Harvoni wins.
you never know when the big boys are going to run the price up that's why it's always important keep core position in a stock like Gild u always have to have a position in it
How about that call! Weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
If the market takes GILD's price down due to ABBV's approval, I'm going in full margin. Nice trade btw.
SNY pulling out was the sell signal.
"Buy the stock hand over fist and here's why:
Big funds are rotating in and out of their positions and this affects GILD since it has 1.5 billion shares floating. This has nothing to do with the value of the stock. It's like free money is being given. Because there is such large tute ownership, they are hedging and shorting, but that will end soon as RX numbers crush all time highs 10k plus RX's this Friday I'm guestimating.
The ABBVI/Enta threat is overstated. With more sales reps and resources thrown into HEP C patient education, more Hep C patient screening, product info via ads, provider education visa vis conferences, presentations, the overall size of the treatment market is going to expand. It's a very safe bet that the ABBV reps will unintentionally remind providers to RX Harvoni since it is superior to ABBV's product.
The overall market collapse will not affect prescriptions for GILD products. The price of oil going down is going to reduce GILD"s fixed expenses: fuel for company cars, heat/air conditioning, electric etc., it's a net plus for the company. The FED will be dovish and gas isn't staying near lows for long imo.
This is a prime opportunity to buy low in a juggernaut company that is ridiculously undervalued for no reason."
Bio-pharma is the place to park money especially in light of the upcoming January effect. The oil situation is to be taken seriously but its impact on GILD is non-existent except the lower costs for the company in utilities, gas expenses for the sales force, shipping etc. The market needs to wise up and put money where oil has no say in GILD's future growth. ABBV's & Enta's share price decline is very interesting considering their PDUFA is around the corner. Is the market reevaluating the Norvir potion? Ask any provider that knows about Harvoni and they say it's their first line rx. We should see 10,000 plus RX's for last week. Guess the providers aren't warehousing for ABBVI's product lol.
Looks promising. Speculative until data is revealed. I can't get my arms around how Ctix could get such a promising drug for practically nothing. I'm full of doubt lol.
Thanks for the info.
Phase 3 studies will tell the tale.
Has the numbness and tingling issue been addressed? I am doing DD on this and haven't come across anything, but that doesn't mean it hasn't been addressed.
Brilacidin is described as a peptide mimetic. It exerts antimicrobial effects by disrupting bacterial membranes. Brilacidin belongs to a new class of antibiotics the manufacturer has dubbed defensin-mimetics. Defensin-mimetics are designed to function similarly to existing host proteins called defensins. This novel mechanism translates to broad gram-positive and gram-negative activity. Current data on brilacidin show activity against ESBLs, and the manufacturer suggests activity against methicillin-resistant Staphylococcus aureus, Enterococcus faecium and NDM-1-producing K. pneumoniae. At this time, there is insufficient data regarding brilacidin’s coverage of Pseudomonas.
In addition, brilacidin has no activity against Acinetobacter baumannii. Recently, a phase 2 trial was completed that compared brilacidin with daptomycin for the treatment of acute bacterial skin and skin structure infections. Brilacidin met all objectives of efficacy and safety in this study. Of note, 65% to 87% of patients in the phase 2 trial experienced adverse events of numbness and tingling. The significance of this is unclear at this time, and the manufacturer is moving forward with a phase 2B study of brilacidin.
http://www.healio.com/infectious-disease/emerging-diseases/news/print/infectious-disease-news/%7B2d636304-7271-44d3-98a7-fd061a787883%7D/pipeline-or-pipe-dream-new-antibiotics-for-multidrug-resistant-gram-negative-bacilli
Are you kidding?
What's the explanation for "numbness and tingling" issue with Brilacidin?:
Brilacidin is described as a peptide mimetic. It exerts antimicrobial effects by disrupting bacterial membranes. Brilacidin belongs to a new class of antibiotics the manufacturer has dubbed defensin-mimetics. Defensin-mimetics are designed to function similarly to existing host proteins called defensins. This novel mechanism translates to broad gram-positive and gram-negative activity. Current data on brilacidin show activity against ESBLs, and the manufacturer suggests activity against methicillin-resistant Staphylococcus aureus, Enterococcus faecium and NDM-1-producing K. pneumoniae. At this time, there is insufficient data regarding brilacidin’s coverage of Pseudomonas.
In addition, brilacidin has no activity against Acinetobacter baumannii. Recently, a phase 2 trial was completed that compared brilacidin with daptomycin for the treatment of acute bacterial skin and skin structure infections. Brilacidin met all objectives of efficacy and safety in this study. Of note, 65% to 87% of patients in the phase 2 trial experienced adverse events of numbness and tingling. The significance of this is unclear at this time, and the manufacturer is moving forward with a phase 2B study of brilacidin.
http://www.healio.com/infectious-disease/emerging-diseases/news/print/infectious-disease-news/%7B2d636304-7271-44d3-98a7-fd061a787883%7D/pipeline-or-pipe-dream-new-antibiotics-for-multidrug-resistant-gram-negative-bacilli
This thing is going to .50 at this rate geez what a stinker.
They will have to raise $$$ via dilution or get a partnership that will be to their disadvantage at this point. Plus it's a stinky pinky with zero transparency. Just hope and faith that a two man show is honest, not playing monkey business with investors as we know all pinkys are honest and beyond reproach.
Bob, I told you to put all of the chips on red 69! ;)
I meant the chart will like.
Look at the daily chart on stockcharts and you will see the MACD is lined up very strong. The chart won't like imo.